PDF(Pubmed)
Abstract：
BACKGROUND: Psoriasis is a common, chronic, and non-contagious skin disease that has no known cause or treatment. Various medical costs for skin disorders, including psoriasis, can be expensive and lifelong. The purpose of the present study was to determine the economic burden of psoriasis in patients admitted to general hospitals affiliated with Shiraz University of Medical Sciences, Iran in 2022.
METHODS: This research was a descriptive, cross-sectional, cost of illness study from a societal perspective. All psoriasis patients (N = 118) admitted to the hospitals affiliated with Shiraz University of Medical Sciences in 2022 were examined. 7 participants refused to cooperate and were excluded from the study and, the information of 111 patients was collected. A researcher-made data collection form was used to collect data. A prevalence-based approach was used to prepare cost data, and the costing approach was bottom-up. The productivity lost due to the absenteeism of patients and their companions was estimated using the human capital approach. Microsoft Excel ® 2016 was applied to analyze the data.
RESULTS: The mean annual cost per psoriasis patient was estimated to be US$ 30,374.21. Its highest and lowest share was related to direct medical costs (88.61%), direct non-medical costs (7.3%) and indirect costs (4.09%), respectively. Also, the highest mean direct medical, direct non-medical, and indirect costs per patient were related to those of medicine (93.11%), transportation (51.65%), and absenteeism of the patients\' companions due to patient care (71.73%).
CONCLUSIONS: Considering that the major contributor in the direct medical cost of treating psoriasis patients was related to medicine, designing appropriate mechanisms for insurance coverage, and allocating government subsidies for the purchase of medicine, are suggested. The result of the current study has important implications for policymakers in developing guidelines for early diagnosis of this disease and reducing the health economic burden.
METHODS: This research was a descriptive, cross-sectional, cost of illness study from a societal perspective. All psoriasis patients (N = 118) admitted to the hospitals affiliated with Shiraz University of Medical Sciences in 2022 were examined. 7 participants refused to cooperate and were excluded from the study and, the information of 111 patients was collected. A researcher-made data collection form was used to collect data. A prevalence-based approach was used to prepare cost data, and the costing approach was bottom-up. The productivity lost due to the absenteeism of patients and their companions was estimated using the human capital approach. Microsoft Excel ® 2016 was applied to analyze the data.
RESULTS: The mean annual cost per psoriasis patient was estimated to be US$ 30,374.21. Its highest and lowest share was related to direct medical costs (88.61%), direct non-medical costs (7.3%) and indirect costs (4.09%), respectively. Also, the highest mean direct medical, direct non-medical, and indirect costs per patient were related to those of medicine (93.11%), transportation (51.65%), and absenteeism of the patients\' companions due to patient care (71.73%).
CONCLUSIONS: Considering that the major contributor in the direct medical cost of treating psoriasis patients was related to medicine, designing appropriate mechanisms for insurance coverage, and allocating government subsidies for the purchase of medicine, are suggested. The result of the current study has important implications for policymakers in developing guidelines for early diagnosis of this disease and reducing the health economic burden.
摘要：
背景：银屑病是常见的，慢性，和无已知病因或治疗的非传染性皮肤病。皮肤病的各种医疗费用，包括牛皮癣,可以是昂贵的和终身的。本研究的目的是确定在设拉子医科大学附属综合医院收治的银屑病患者的经济负担。伊朗2022年
方法：这项研究是描述性的，横截面,从社会角度研究疾病成本。对2022年入住设拉子医科大学附属医院的所有银屑病患者（N=118）进行了检查。7名参与者拒绝合作，被排除在研究之外，收集了111例患者的信息。使用研究人员制作的数据收集表收集数据。使用基于患病率的方法来准备成本数据，成本计算方法是自下而上的。使用人力资本方法估算了由于患者及其同伴缺勤而导致的生产力损失。MicrosoftExcel®2016用于分析数据。
结果：估计每位银屑病患者的平均年费用为30,374.21美元。其最高和最低的份额与直接医疗费用有关(88.61%)，直接非医疗费用(7.3%)和间接成本(4.09%)，分别。此外，最高平均直接医疗，直接非医疗，每位患者的间接成本与药物相关(93.11%)，交通运输（51.65%），以及因患者护理而导致的患者陪伴缺勤(71.73%)。
结论：考虑到治疗银屑病患者的直接医疗费用的主要贡献者与药物有关，设计适当的保险覆盖机制，并分配政府购买药品的补贴，是建议的。本研究的结果对政策制定者制定该疾病的早期诊断指南和减轻卫生经济负担具有重要意义。
方法：这项研究是描述性的，横截面,从社会角度研究疾病成本。对2022年入住设拉子医科大学附属医院的所有银屑病患者（N=118）进行了检查。7名参与者拒绝合作，被排除在研究之外，收集了111例患者的信息。使用研究人员制作的数据收集表收集数据。使用基于患病率的方法来准备成本数据，成本计算方法是自下而上的。使用人力资本方法估算了由于患者及其同伴缺勤而导致的生产力损失。MicrosoftExcel®2016用于分析数据。
结果：估计每位银屑病患者的平均年费用为30,374.21美元。其最高和最低的份额与直接医疗费用有关(88.61%)，直接非医疗费用(7.3%)和间接成本(4.09%)，分别。此外，最高平均直接医疗，直接非医疗，每位患者的间接成本与药物相关(93.11%)，交通运输（51.65%），以及因患者护理而导致的患者陪伴缺勤(71.73%)。
结论：考虑到治疗银屑病患者的直接医疗费用的主要贡献者与药物有关，设计适当的保险覆盖机制，并分配政府购买药品的补贴，是建议的。本研究的结果对政策制定者制定该疾病的早期诊断指南和减轻卫生经济负担具有重要意义。
